Literature DB >> 9116610

Clinical strategies for the management of cytomegalovirus infection and disease in allogeneic bone marrow transplant.

H G Prentice1, P Kho.   

Abstract

Four clinical strategies are proposed for the management of CMV disease: prophylaxis, suppression, pre-emptive therapy and treatment. The degree of risk of developing CMV disease and the safety profile of the presently available drugs need to be considered when deciding on the most appropriate approach. We conclude that a prophylactic strategy employing a drug with a safe toxicity profile followed by pre-emptive treatment with an effective antiviral drug for failure of prophylaxis gives the best outcome in allogeneic HLA matched bone marrow transplant recipients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9116610     DOI: 10.1038/sj.bmt.1700630

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  9 in total

1.  Clinical relevance of direct quantification of pp65 antigenemia using flow cytometry in solid organ and stem cell transplant recipients.

Authors:  A S Poirier-Toulemonde; N Milpied; D Cantarovich; J F Morcet; S Billaudel; B M Imbert-Marcille
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

Review 2.  Prophylaxis against herpesvirus infections in transplant recipients.

Authors:  P Ljungman
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Real-time PCR diagnostics failure caused by nucleotide variability within exon 4 of the human cytomegalovirus major immediate-early gene.

Authors:  Martina Lengerova; Zdenek Racil; Pavlina Volfova; Jana Lochmanova; Jitka Berkovcova; Dana Dvorakova; Jiri Vorlicek; Jiri Mayer
Journal:  J Clin Microbiol       Date:  2007-01-17       Impact factor: 5.948

4.  A cross-Canada survey of cytomegalovirus prevention and treatment practices in bone marrow transplant recipients.

Authors:  A Humar; J Lipton; H Messner; A McGeer; T Mazzulli
Journal:  Can J Infect Dis       Date:  1999-11

5.  Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation.

Authors:  C Solano; I Muñoz; A Gutiérrez; A Farga; F Prósper; J García-Conde; D Navarro; C Gimeno
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

Review 6.  Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.

Authors:  J K McGavin; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

7.  Normalized quantification of human cytomegalovirus DNA by competitive real-time PCR on the LightCycler instrument.

Authors:  Markus Stöcher; Jörg Berg
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

Review 8.  Overview of Human Cytomegalovirus Pathogenesis.

Authors:  Heather L Fulkerson; Maciej T Nogalski; Donna Collins-McMillen; Andrew D Yurochko
Journal:  Methods Mol Biol       Date:  2021

9.  Determination of human cytomegalovirus pp65 antigenemia among renal transplant patients.

Authors:  S Moses; J Malathi; N R Singha; R Bagyalakshmi; H N Madhavan
Journal:  Indian J Nephrol       Date:  2012-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.